Management of Myositis-Related Interstitial Lung Disease

Julie Morisset, Cheilonda Johnson, Eric Rich, Harold R. Collard, Joyce S. Lee

Research output: Contribution to journalReview article

Abstract

Interstitial lung disease (ILD) is a frequent pulmonary manifestation and an important cause of morbidity and mortality in patients with idiopathic inflammatory myopathy. Myositis-related ILD presents a therapeutic challenge for clinicians, as there are no available guidelines to help with management decisions. This review covers the existing evidence on the pharmacologic and nonpharmacologic management of myositis-related ILD, highlighting the lack of randomized controlled data to guide treatment. Given the absence of existing guidelines to inform treatment decisions, we provide a comprehensive summary, including dosing, side effects, and suggested monitoring of the commonly used immunosuppressive agents and a proposed treatment algorithm based on the existing literature.

Original languageEnglish (US)
Pages (from-to)1118-1128
Number of pages11
JournalChest
Volume150
Issue number5
DOIs
StatePublished - Nov 1 2016

Keywords

  • interstitial lung disease
  • myositis
  • treatment

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Management of Myositis-Related Interstitial Lung Disease'. Together they form a unique fingerprint.

  • Cite this

    Morisset, J., Johnson, C., Rich, E., Collard, H. R., & Lee, J. S. (2016). Management of Myositis-Related Interstitial Lung Disease. Chest, 150(5), 1118-1128. https://doi.org/10.1016/j.chest.2016.04.007